William Blair analyst Brandon Vazquez has maintained their bullish stance on CVRX stock, giving a Buy rating on November 3.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Brandon Vazquez has given his Buy rating due to a combination of factors that highlight CVRx’s positive trajectory. The company’s third-quarter sales have slightly exceeded expectations, driven by strategic commercial, clinical, and reimbursement advancements. The investment in training new sales representatives is starting to pay off, as they are becoming more effective in their roles.
Additionally, CVRx’s shift in commercial strategy to focus on building robust Barostim programs and enhancing existing accounts is showing promising results. With increased utilization and improved productivity among top sales representatives, the company is on a path to achieving its growth targets. The current enterprise value, coupled with a realistic fourth-quarter outlook, positions CVRx favorably for continued growth into 2026.
Vazquez covers the Healthcare sector, focusing on stocks such as Ceribell, Inc., Penumbra, and PROCEPT BioRobotics. According to TipRanks, Vazquez has an average return of -0.8% and a 42.47% success rate on recommended stocks.
In another report released on November 3, Lake Street also maintained a Buy rating on the stock with a $14.00 price target.